Therefore, we searched for drugs effectively targeting SQSTM1/p62 and found that the anti-tumor drug DDP significantly reduced the expression level of SQSTM1/p62 in SQSTM1 WT HepG2 cells at 2.5–10 μM (Figure 7A). Here, SQSTM1 is linked to neoplasm.